Cite
PB2288: INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON‐HODGKIN’S LYMPHOMA BEFORE AND DURING THE COVID‐19 PANDEMIC IN ISRAEL ‐ A SINGLE CENTER RETROSPECTIVE STUDY.
MLA
Bronstein, Yotam, et al. “Pb2288: Incidence of Newly Diagnosed Aggressive Non‐Hodgkin’s Lymphoma Before and during the Covid‐19 Pandemic in Israel ‐ a Single Center Retrospective Study.” HemaSphere, vol. 7, Aug. 2023, pp. 1–2. EBSCOhost, https://doi.org/10.1097/01.HS9.0000975880.60805.b6.
APA
Bronstein, Y., Feigin, E., Avivi, I., Joffe, E., & Perry, C. (2023). Pb2288: Incidence of Newly Diagnosed Aggressive Non‐Hodgkin’s Lymphoma Before and during the Covid‐19 Pandemic in Israel ‐ a Single Center Retrospective Study. HemaSphere, 7, 1–2. https://doi.org/10.1097/01.HS9.0000975880.60805.b6
Chicago
Bronstein, Yotam, Eugene Feigin, Irit Avivi, Erel Joffe, and Chava Perry. 2023. “Pb2288: Incidence of Newly Diagnosed Aggressive Non‐Hodgkin’s Lymphoma Before and during the Covid‐19 Pandemic in Israel ‐ a Single Center Retrospective Study.” HemaSphere 7 (August): 1–2. doi:10.1097/01.HS9.0000975880.60805.b6.